Summary
AbbVie Inc. (ABBV) has filed a Form 8-K to provide preliminary information regarding its first quarter 2026 financial results, specifically detailing the impact of acquired In-Process Research & Development (IPR&D) and milestones expenses. The company anticipates these expenses will negatively impact both GAAP and adjusted non-GAAP diluted earnings per share by approximately $0.41. This expense, totaling $744 million pre-tax, was not previously included in the company's initial 2026 adjusted diluted EPS guidance, which was based on February 4, 2026, expectations. Despite this one-time charge, AbbVie has updated its full-year 2026 adjusted diluted EPS guidance to a range of $13.96 to $14.16, incorporating the first quarter's impact. The updated first quarter 2026 adjusted diluted EPS guidance range is now projected at $2.56 to $2.60. Investors should note that these are preliminary estimates and the final results are subject to financial statement closing procedures. The filing also includes standard forward-looking statement disclaimers highlighting potential risks and uncertainties.
Key Highlights
- 1AbbVie anticipates a $0.41 negative impact on both GAAP and adjusted non-GAAP diluted EPS for Q1 2026 due to acquired IPR&D and milestones expenses.
- 2The pre-tax impact of acquired IPR&D and milestones expenses for Q1 2026 is estimated at $744 million.
- 3The previously issued 2026 adjusted diluted EPS guidance did not account for potential acquired IPR&D and milestones expenses.
- 4AbbVie has updated its full-year 2026 adjusted diluted EPS guidance to a range of $13.96 - $14.16, now including the Q1 expense impact.
- 5The updated Q1 2026 adjusted diluted EPS guidance range, including the expense impact, is set at $2.56 - $2.60.
- 6The reported results are preliminary and subject to finalization and financial statement closing procedures.
- 7Exhibit 99.1 contains updated guidance, including the estimated acquired IPR&D and milestones expense for Q1 2026.